This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.

The place of checkpoint inhibitors (anti-PD-1 and PD-L-1) is currently validated in the management of melanoma and metastatic non-small cell lung cancer. The toxicity profile is specific with adverse effects related to immunity. Some side effects (myocarditis, colitis, interstitial lung disease, etc.) can be severe and patient could be hospitalized in intensive care unit.

The question of immunotherapy's imputability in the acute disease is becoming more frequent.

Inclusion Criteria:

• > or = 18 years old;
• with a solid tumor;
• Treatment with anti-CTLA4 and / or anti-PD-1 / PDL-1 still in progress or up to 6 months after stopping;
• Admitted to resuscitation or continuous care in an unprogrammed way, whatever the reason.

Exclusion Criteria:

• Minors;
• Pregnant or lactating woman;
• Admission after surgery of a scheduled surgery or for the security of procedure;
• Anti-CTLA4 and / or anti-PD-1 / PDL-1 treatment stopped for more than 6 months;
• Subject under guardianship or deprivation of liberty;
• Refusal of consent;
• No affiliation to a health insurance scheme.

Cancer patients treated with anti-CTLA4 and/or anti-PD-1 / anti-PD-L1 or up to 6 months after stopping admitted in ICU